AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Dr. Eric von Hofe named VP for product development and scientific affairs.
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corp. (GNBT) announced that Dr. Eric von Hofe, PhD, an executive with the company's Antigen Express subsidiary, has been appointed as the company's vice president in charge of product development and scientific affairs.
"We are pleased that Dr. von Hofe has agreed to assume this important role on our team," said Anna Gluskin, the company's president and CEO. "In conjunction with our on-going implementation of the global clinical and regulatory program for Oralin, Dr. von Hofe will spearhead the development of other applications of our proprietary oral-spray formulation drug-delivery technology such as heparin, fentanyl, and morphine, which should offer patent extensions for ...
- Generex Biotechnology's Subsidiary Antigen Express Appoints Eric von Hofe as...
- Press release article from: PR Newswire November 4, 2003 700+ words
...today that its Antigen Express subsidiary for...appointed Eric von Hofe, Ph.D. as...delighted to have Dr. von Hofe join Antigen Express," said Dr...to be joining Antigen Express," said Dr. von Hofe. "The company...
- Eric von Hofe.(Newsmakers)(elected vice president of technology development at...
- Magazine article from: Chain Drug Review November 24, 2003 700+ words
Eric von Hofe has been elected vice president of technology development at Antigen Express, a subsidiary of Generex Biotechnology Inc. He had been director of programs and operations as well as discovery research at Millennium Pharmaceuticals Inc.
- Dr. Eric von Hofe Appointed Generex VP for Product Development & Scientific...
- Press release article from: PR Newswire October 7, 2004 700+ words
...Dr. Eric von Hofe, Ph.D...Company's Antigen Express subsidiary...Dr. von Hofe will continue...Company's Antigen Express subsidiary...to joining Antigen Express in November, 2003, Dr. von Hofe was Director...
- Eric von Hofe.(Newsmakers)(appointed at Generex Biotechnology Corp. )(Brief...
- Magazine article from: Chain Drug Review October 25, 2004 700+ words
Eric von Hofe has been elected vice president of product development and scientific affairs at Generex Biotechnology Corp. He had been an executive with Generex' Antigen Express unit.
- Generex Sub Antigen Express Makes Proposals For Co-Development Of Flu Vaccine.
- News wire article from: The America's Intelligence Wire November 10, 2005 700+ words
...technology being employed at Antigen Express for the potentially pandemic...H5N1 influenza virus." Antigen Express has extant collaborations...China," said Dr. Eric von Hofe, president of Antigen Express. "The danger posed by avian...
- Invited Cancer Treatment Review Describes Novel in Situ Cancer Vaccine to Cure...
- Press release article from: PR Newswire April 14, 2004 700+ words
...President, Biology at Antigen Express, has been responsible...to the tumor." The Antigen Express immunotherapy technology...mechanism. Dr. Eric von Hofe, Vice President, Technology Development at Antigen Express said: "This paper...
- Generex Biotechnology Completes Acquisition of Antigen Express.
- Press release article from: PR Newswire August 11, 2003 700+ words
...shares in the capital of Antigen Express, Inc. in exchange for approximately...Officer and a director of Antigen Express. Dr. Gulfo is also expected...of directors of Generex. Antigen Express will operate as a wholly...
- Generex Biotechnology Announces Proposed Acquisition of Antigen Express, Inc.
- Press release article from: PR Newswire June 5, 2003 700+ words
...of the shares of privately-owned Antigen Express, Inc. in exchange for a maximum...depends on satisfaction of certain Antigen Express performance milestones over the next...Respiratory Syndrome) vaccines with Antigen Express. These vaccines combine the Company...
- Antigen Express Announces Phase I SBIR Grant for Development of MHC Class II...
- Press release article from: PR Newswire April 5, 2001 700+ words
...Mass., April 5 /PRNewswire/ -- Antigen Express, Inc. (AgExp) today announced...dendritic cell based therapeutics. Antigen Express researchers have shown that cancer...metastasizing prostate cancer cell line, Antigen Express researchers aim to first induce MHC...
- Generex Biotechnology's Subsidiary Enters into Collaboration to Develop SARS...
- Press release article from: PR Newswire February 23, 2004 700+ words
...which can be used in a DNA vaccine. Antigen Express, Generex's subsidiary, has developed...protection against SARS infections. Antigen Express' technology focuses on modulating...DNA vaccines. "The heart of the Antigen Express technology platform is controlling...
Source: HighBeam Research, Dr. Eric von Hofe named VP for product development and scientific...